dc.creator | Gómez Rodríguez, Blas José | es |
dc.creator | Castro Laria, Luisa | es |
dc.creator | Argüelles Arias, Federico | es |
dc.creator | Castro Márquez, Cristina | es |
dc.creator | Caunedo-Álvarez, Ángel | es |
dc.creator | Romero Gómez, Manuel | es |
dc.date.accessioned | 2024-05-16T16:15:15Z | |
dc.date.available | 2024-05-16T16:15:15Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | Gómez Rodríguez, B.J., Castro Laria, L., Argüelles Arias, F., Castro Márquez, C., Caunedo-Álvarez, Á. y Romero Gómez, M. (2017). A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patients. Revista Española de Enfermedades Digestivas, 109 (8), 552-558. https://doi.org/10.17235/reed.2017.4809/2016. | |
dc.identifier.issn | 1130-0108 | es |
dc.identifier.issn | 2340-4167 | es |
dc.identifier.uri | https://hdl.handle.net/11441/158471 | |
dc.description.abstract | Objective: To evaluate the efficacy and safety of a quadruple
regimen (BMTO) of the “3-in-1 capsule” (containing bismuth
subcitrate potassium, metronidazole and tetracycline) plus
omeprazole in naïve and previously treated patients diagnosed with
Helicobacter pylori (H. pylori) infection in the clinical setting in
Seville (Spain).
Methods: This is a prospective study carried out on
consecutive patients with a confirmed H. pylori infection and
upper gastrointestinal symptoms. After providing their informed
consent, the patients were treated for ten days with a 3-in-1 capsule
containing bismuth subcitrate potassium (140 mg), metronidazole
(125 mg) and tetracycline (125 mg: Pylera®), three capsules four
times daily, plus omeprazole (20 or 40 mg) twice daily. Eradication
of infection was determined by a negative urea breath test at least
28 days after the end of treatment.
Results: A total of 58 consecutive patients were enrolled into
this study, two of whom withdrew early due to vomiting on days
three and five, respectively. In this cohort, 17 patients (29.3%) had
a prior history of medication to treat H. pylori. In the intent-to
treat population, eradication was achieved in 97.6% (40/41) and
82.4% (14/17) of cases in patients treated with BMTO as a first
line or rescue therapy, respectively. At least one adverse event was
reported by 28 (48%) patients, mostly mild effects (86%).
Conclusion: A ten day treatment with BMTO is an effective
and safe strategy to combat confirmed H. pylori infection in
patients. | es |
dc.format | application/pdf | es |
dc.format.extent | 6 p. | es |
dc.language.iso | eng | es |
dc.publisher | Aran Ediciones S.A. | es |
dc.relation.ispartof | Revista Española de Enfermedades Digestivas, 109 (8), 552-558. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Helicobacter pylori | es |
dc.subject | Bismuth-based quadruple therapy | es |
dc.subject | Pylera® | es |
dc.subject | Eradication | es |
dc.title | A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patients | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://www.reed.es/ArticuloFicha.aspx?id=2381&hst=0&idR=51&tp=1 | es |
dc.identifier.doi | 10.17235/reed.2017.4809/2016 | es |
dc.journaltitle | Revista Española de Enfermedades Digestivas | es |
dc.publication.volumen | 109 | es |
dc.publication.issue | 8 | es |
dc.publication.initialPage | 552 | es |
dc.publication.endPage | 558 | es |